Actively Recruiting
Phase 12 Study of SAR445877 Alone or With Other Cancer Treatments in Adults With Advanced Solid Tumors
Led by Sanofi · Updated on 2026-06-23
542
Participants Needed
22
Research Sites
75 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and early effectiveness of SAR445877, a new drug given alone or with other cancer treatments, in adults aged 18 and older who have advanced solid tumors that cannot be surgically removed or have spread. This Phase 12 open-label study includes participants who have limited or no standard treatment options, aiming to find the best dose and assess how well SAR445877 works in different combinations. The study has two parts Part 1 focuses on gradually increasing doses of SAR445877 given intravenously every one or two weeks to find safe and effective doses alone or with other therapies like cetuximab, ADG126, or bevacizumab. Part 2 expands to multiple groups testing SAR445877 at recommended doses, either alone or combined with these other anticancer drugs, in various cancer types such as melanoma, non-small cell lung cancer, colorectal, gastric, and liver cancers. Participants undergo a screening period of up to 28 days before starting treatment, which continues until the cancer progresses, unacceptable side effects occur, or other reasons require stopping. After treatment ends, there is a follow-up period to monitor outcomes until disease progression, new therapy, death, or withdrawal. Throughout the study, researchers collect safety data, tumor response measures, drug levels in the body, and immune responses to evaluate the effects of SAR445877 and combinations for up to two years.
CONDITIONS
Brief Title
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Research Team
T
Trial Transparency email recommended (Toll free for US & Canada)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here